Switch to:
Also traded in: Austria, Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.13
BAYRY's Cash-to-Debt is ranked lower than
61% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. BAYRY: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
BAYRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.25 Max: No Debt
Current: 0.13
0.08
No Debt
Equity-to-Asset 0.35
BAYRY's Equity-to-Asset is ranked lower than
67% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BAYRY: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
BAYRY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: 0.51
Current: 0.35
0.21
0.51
Debt-to-Equity 1.11
BAYRY's Debt-to-Equity is ranked lower than
54% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BAYRY: 1.11 )
Ranked among companies with meaningful Debt-to-Equity only.
BAYRY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16  Med: 0.68 Max: 1.72
Current: 1.11
0.16
1.72
Debt-to-EBITDA 6.27
BAYRY's Debt-to-EBITDA is ranked higher than
57% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. BAYRY: 6.27 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BAYRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.09  Med: 1.88 Max: 6.27
Current: 6.27
1.09
6.27
Interest Coverage 6.47
BAYRY's Interest Coverage is ranked lower than
75% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. BAYRY: 6.47 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.86  Med: 5.58 Max: 6.99
Current: 6.47
2.86
6.99
Piotroski F-Score: 4
Altman Z-Score: 0.95
Beneish M-Score: -2.26
WACC vs ROIC
5.35%
8.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 16.69
BAYRY's Operating Margin % is ranked higher than
79% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. BAYRY: 16.69 )
Ranked among companies with meaningful Operating Margin % only.
BAYRY' s Operating Margin % Range Over the Past 10 Years
Min: 7.78  Med: 12.94 Max: 17.45
Current: 16.69
7.78
17.45
Net Margin % 19.25
BAYRY's Net Margin % is ranked higher than
85% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. BAYRY: 19.25 )
Ranked among companies with meaningful Net Margin % only.
BAYRY' s Net Margin % Range Over the Past 10 Years
Min: 3.71  Med: 7.35 Max: 20.95
Current: 19.25
3.71
20.95
ROE % 17.65
BAYRY's ROE % is ranked higher than
85% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. BAYRY: 17.65 )
Ranked among companies with meaningful ROE % only.
BAYRY' s ROE % Range Over the Past 10 Years
Min: 6.9  Med: 14.63 Max: 21.85
Current: 17.65
6.9
21.85
ROA % 7.60
BAYRY's ROA % is ranked higher than
78% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. BAYRY: 7.60 )
Ranked among companies with meaningful ROA % only.
BAYRY' s ROA % Range Over the Past 10 Years
Min: 2.54  Med: 5.19 Max: 9.33
Current: 7.6
2.54
9.33
ROC (Joel Greenblatt) % 29.29
BAYRY's ROC (Joel Greenblatt) % is ranked higher than
80% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. BAYRY: 29.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BAYRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.91  Med: 26.93 Max: 32.11
Current: 29.29
17.91
32.11
3-Year Revenue Growth Rate -7.00
BAYRY's 3-Year Revenue Growth Rate is ranked lower than
83% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BAYRY: -7.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BAYRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 2.5 Max: 11.1
Current: -7
-10.6
11.1
3-Year EBITDA Growth Rate -2.40
BAYRY's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. BAYRY: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BAYRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.2  Med: 4.2 Max: 15.4
Current: -2.4
-23.2
15.4
3-Year EPS without NRI Growth Rate -2.50
BAYRY's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. BAYRY: -2.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BAYRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.8 Max: 39.3
Current: -2.5
0
39.3
GuruFocus has detected 1 Warning Sign with Bayer AG BAYRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BAYRY's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

BAYRY Guru Trades in Q3 2017

Barrow, Hanley, Mewhinney & Strauss 1,261,356 sh (New)
Ken Fisher 20,620,341 sh (+4.48%)
» More
Q4 2017

BAYRY Guru Trades in Q4 2017

Ken Fisher 20,838,342 sh (+1.06%)
Barrow, Hanley, Mewhinney & Strauss Sold Out
» More
Q1 2018

BAYRY Guru Trades in Q1 2018

Ken Fisher 21,668,714 sh (+3.98%)
» More
Q2 2018

BAYRY Guru Trades in Q2 2018

Ken Fisher 20,679,488 sh (-4.57%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -4.57%0.04%$27.49 - $31.67 $ 22.34-25%20,679,488
Ken Fisher 2018-03-31 Add 3.98%0.03%$27.75 - $33.71 $ 22.34-27%21,668,714
Ken Fisher 2017-12-31 Add 1.06%0.01%$30.78 - $35.29 $ 22.34-32%20,838,342
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Sold Out 0.06%$30.78 - $35.29 $ 22.34-32%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:GSK, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, NYSE:ABBV, NYSE:MRK, TSE:4503, TSE:4519, TSE:4578, XSWX:NOVN, TSE:4568, HKSE:01093, XSWX:ROG, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC » details
Traded in other countries:BAYN.Austria, BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Headquarter Location:Germany
Bayer AG is active in the German healthcare sector. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and animal health products.

Bayer is a German healthcare and chemical conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and animal health products. The company has a crop science business that includes pesticides, herbicides, and fungicides, as well as a material science segment that produces plastics, including polyurethane and polycarbonate. The remaining ownership of the material science group is likely to be sold in the near term.

Top Ranked Articles about Bayer AG

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bayer Aktiengesellschaft - BAYRY
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bayer Aktiengesellschaft - BAYRY
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bayer Aktiengesellschaft (BAYRY)
Bayer Closes Merger With Buffett’s Monsanto Combined company expects to improve productivity and sustainability of agricultural companies
Bayer AG (XTER:BAYN)(BAYRY) announced on Thursday that it closed its merger with Monsanto Co. (NYSE:MON), a company Warren Buffett (Trades, Portfolio) invested in 7.26 million shares during the first quarter. Read more...
David Herro Starts 4 Positions in 4th Quarter Guru’s largest new stake is in Bayer
David Herro (Trades, Portfolio), portfolio manager of the Oakmark International Fund, disclosed he established four new positions when he released his first-quarter portfolio last week. Read more...
Justice Department Approves Bayer’s Acquisition of Monsanto The company agreed to sell more assets to competitor
After months of back-and-forth negotiations between Bayer AG (XTER:BAYN) (BAYRY) and regulators, the Wall Street Journal reported on Monday the company made a deal with the U.S. Justice Department for antitrust approval of its $62.5 billion takeover of Monsanto Co. (NYSE:MON). Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.02
BAYRY's PE Ratio is ranked higher than
89% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. BAYRY: 10.02 )
Ranked among companies with meaningful PE Ratio only.
BAYRY' s PE Ratio Range Over the Past 10 Years
Min: 8.76  Med: 22.41 Max: 36.41
Current: 10.02
8.76
36.41
Forward PE Ratio 10.54
BAYRY's Forward PE Ratio is ranked higher than
78% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. BAYRY: 10.54 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.78
BAYRY's PE Ratio without NRI is ranked higher than
56% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. BAYRY: 19.78 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAYRY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.53  Med: 23.84 Max: 36.98
Current: 19.78
14.53
36.98
Price-to-Owner-Earnings 7.53
BAYRY's Price-to-Owner-Earnings is ranked higher than
93% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. BAYRY: 7.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAYRY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.97  Med: 14.14 Max: 27.55
Current: 7.53
6.97
27.55
PB Ratio 1.44
BAYRY's PB Ratio is ranked higher than
61% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. BAYRY: 1.44 )
Ranked among companies with meaningful PB Ratio only.
BAYRY' s PB Ratio Range Over the Past 10 Years
Min: 1.33  Med: 2.6 Max: 5.47
Current: 1.44
1.33
5.47
PS Ratio 1.95
BAYRY's PS Ratio is ranked higher than
62% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BAYRY: 1.95 )
Ranked among companies with meaningful PS Ratio only.
BAYRY' s PS Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.61 Max: 2.92
Current: 1.95
0.86
2.92
Price-to-Free-Cash-Flow 12.29
BAYRY's Price-to-Free-Cash-Flow is ranked higher than
82% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. BAYRY: 12.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAYRY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.15  Med: 15.93 Max: 244.92
Current: 12.29
7.15
244.92
Price-to-Operating-Cash-Flow 8.69
BAYRY's Price-to-Operating-Cash-Flow is ranked higher than
84% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. BAYRY: 8.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAYRY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.42  Med: 10.26 Max: 19.1
Current: 8.69
5.42
19.1
EV-to-EBIT 19.91
BAYRY's EV-to-EBIT is ranked higher than
71% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. BAYRY: 19.91 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 16.35 Max: 27
Current: 19.91
7.6
27
EV-to-EBITDA 13.70
BAYRY's EV-to-EBITDA is ranked higher than
79% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. BAYRY: 13.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 9.4 Max: 16.9
Current: 13.7
4.3
16.9
EV-to-Revenue 3.24
BAYRY's EV-to-Revenue is ranked higher than
66% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. BAYRY: 3.24 )
Ranked among companies with meaningful EV-to-Revenue only.
BAYRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 1.9 Max: 4
Current: 3.24
0.8
4
PEG Ratio 8.95
BAYRY's PEG Ratio is ranked lower than
89% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. BAYRY: 8.95 )
Ranked among companies with meaningful PEG Ratio only.
BAYRY' s PEG Ratio Range Over the Past 10 Years
Min: 1.13  Med: 3.38 Max: 28.98
Current: 8.95
1.13
28.98
Shiller PE Ratio 18.41
BAYRY's Shiller PE Ratio is ranked higher than
72% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. BAYRY: 18.41 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAYRY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.06  Med: 28.73 Max: 44.96
Current: 18.41
17.06
44.96
Current Ratio 1.41
BAYRY's Current Ratio is ranked higher than
53% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. BAYRY: 1.41 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.55 Max: 2.53
Current: 1.41
1
2.53
Quick Ratio 1.00
BAYRY's Quick Ratio is ranked higher than
53% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. BAYRY: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.04 Max: 2.04
Current: 1
0.64
2.04
Days Inventory 238.04
BAYRY's Days Inventory is ranked lower than
80% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. BAYRY: 238.04 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.56  Med: 142.56 Max: 263.05
Current: 238.04
126.56
263.05
Days Sales Outstanding 147.64
BAYRY's Days Sales Outstanding is ranked lower than
59% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. BAYRY: 147.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.01  Med: 71.04 Max: 147.64
Current: 147.64
66.01
147.64
Days Payable 147.45
BAYRY's Days Payable is ranked higher than
64% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. BAYRY: 147.45 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 83.03 Max: 199.02
Current: 147.45
54.65
199.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.63
BAYRY's Dividend Yield % is ranked higher than
79% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. BAYRY: 3.63 )
Ranked among companies with meaningful Dividend Yield % only.
BAYRY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.44  Med: 2.51 Max: 3.93
Current: 3.63
1.44
3.93
Dividend Payout Ratio 0.71
BAYRY's Dividend Payout Ratio is ranked lower than
80% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. BAYRY: 0.71 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAYRY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.55 Max: 0.88
Current: 0.71
0.46
0.88
3-Year Dividend Growth Rate 8.70
BAYRY's 3-Year Dividend Growth Rate is ranked higher than
55% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. BAYRY: 8.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAYRY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.7 Max: 34.9
Current: 8.7
0
34.9
Forward Dividend Yield % 3.63
BAYRY's Forward Dividend Yield % is ranked higher than
77% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. BAYRY: 3.63 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.89
BAYRY's 5-Year Yield-on-Cost % is ranked higher than
88% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. BAYRY: 5.89 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAYRY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.33  Med: 4.06 Max: 6.36
Current: 5.89
2.33
6.36

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.88
BAYRY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. BAYRY: 0.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAYRY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.47 Max: 4.03
Current: 0.88
0.78
4.03
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.40
BAYRY's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
60% of the 110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. BAYRY: 1.40 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BAYRY' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.12  Med: 1.66 Max: 3.31
Current: 1.4
1.12
3.31
Price-to-Median-PS-Value 1.21
BAYRY's Price-to-Median-PS-Value is ranked lower than
74% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. BAYRY: 1.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAYRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.78 Max: 1.74
Current: 1.21
0.19
1.74
Earnings Yield (Greenblatt) % 5.03
BAYRY's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. BAYRY: 5.03 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAYRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 6.1 Max: 13.1
Current: 5.03
3.7
13.1
Forward Rate of Return (Yacktman) % 8.26
BAYRY's Forward Rate of Return (Yacktman) % is ranked higher than
53% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. BAYRY: 8.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAYRY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4  Med: 11.4 Max: 25.6
Current: 8.26
4
25.6

More Statistics

Revenue (TTM) (Mil) $42,081.25
EPS (TTM) $ 2.32
Beta1.09
Volatility22.33%
52-Week Range $20.28 - 35.22
Shares Outstanding (Mil)3,487.26 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 45,567 54,557 56,767
EBIT (Mil $) 6,186 9,289 10,464 12,150
EBITDA (Mil $) 10,088 14,471 15,440 17,467
EPS ($) 0.89 1.16 1.58 2.81
EPS without NRI ($) 0.89 1.16 1.58 2.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.06%
Dividends per Share ($) 0.81 0.83 0.84

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}